1. Home
  2. SLDP vs CTNM Comparison

SLDP vs CTNM Comparison

Compare SLDP & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SLDP

Solid Power Inc.

N/A

Current Price

$1.87

Market Cap

552.2M

Sector

Energy

ML Signal

N/A

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

N/A

Current Price

$10.50

Market Cap

550.7M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
SLDP
CTNM
Founded
2011
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Electrical Products
Sector
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
552.2M
550.7M
IPO Year
2021
2024

Fundamental Metrics

Financial Performance
Metric
SLDP
CTNM
Price
$1.87
$10.50
Analyst Decision
Strong Buy
Buy
Analyst Count
2
8
Target Price
$6.88
★ $21.43
AVG Volume (30 Days)
★ 3.1M
692.4K
Earning Date
11-03-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 5.56
0.46
EPS
★ N/A
N/A
Revenue
★ $21,747,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$19.35
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 7.98
N/A
52 Week Low
$1.80
$6.73
52 Week High
$6.35
$17.79

Technical Indicators

Market Signals
Indicator
SLDP
CTNM
Relative Strength Index (RSI) 38.28 51.26
Support Level N/A $6.73
Resistance Level $2.49 $13.72
Average True Range (ATR) 0.12 0.76
MACD -0.00 0.36
Stochastic Oscillator 7.38 77.30

Price Performance

Historical Comparison
SLDP
CTNM

About SLDP Solid Power Inc.

Solid Power Inc develops solid-state battery technology and manufacturing processes. Its sulfide-based solid electrolyte material replaces the liquid or gel electrolyte used in traditional lithium-ion battery cells and enables improvement in energy density, battery life and safety performance. The company produces electrolytes on two pilot manufacturing lines using a batch manufacturing process for customer sampling and internal cell development, and manufactures solid-state cells on pre-pilot and pilot cell manufacturing lines. Its cell manufacturing processes are developed around industry-standard lithium-ion battery manufacturing processes and equipment, and it manufactures all cell designs, including cathodes and anodes, using materials sourced from external suppliers.

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Share on Social Networks: